FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de stacks

Anti-Aging Skin Stack

Anti-Aging & Longevityintermediate

83

synergie

83
Share
Pépétides

3

Moyenne journalière en mcg

5,800

Niveau

intermediate

Ajouté

May 17, 2026

Aperçu

The Anti-Aging Skin Stack combines the three most evidence-backed peptides for skin aging and longevity into a comprehensive protocol that targets collagen synthesis, cellular aging, and GH-driven tissue regeneration simultaneously. GHK-Cu (glycyl-L-histidyl-L-lysine copper) is the anchor of this stack. As a copper-binding tripeptide that naturally declines with age (from ~200ng/mL at age 20 to ~80ng/mL at 60), GHK-Cu activates over 4,000 human genes — more than any other known compound. For skin, it promotes collagen and elastin synthesis, activates fibroblasts, reduces inflammation, and protects against UV damage. Both topical and injectable forms have peer-reviewed human data supporting skin quality improvements. Epithalon works at the cellular aging level. By activating telomerase and regulating the pineal gland''s circadian signaling, it slows two fundamental mechanisms of skin aging: telomere shortening (which drives cellular senescence) and circadian rhythm disruption (which impairs the nighttime skin repair cycle). Epithalon is used in 10-day courses rather than continuously. CJC-1295 provides the GH axis component. GH decline is one of the primary drivers of skin thinning, reduced collagen density, and decreased healing capacity with age. By amplifying nocturnal GH pulses, CJC-1295 increases IGF-1-driven collagen production throughout the body, including skin. The combination of GHK-Cu (direct collagen synthesis) and CJC-1295 (hormonal collagen support) creates a more sustained and comprehensive collagen protection effect.

Protocole de dose

GHK-Cu

Every day· subcutaneous or topical

Lire plus sur GHK-Cu →

500 mcg

par dose

Epithalon

daily (10-day course)· subcutaneous

Lire plus sur Epithalon →

5,000 mcg

par dose

CJC-1295

daily (before bed)· subcutaneous

Lire plus sur CJC-1295 →

300 mcg

par dose

Objectifs & Preuves

Skin anti-agingCollagen productionReduced wrinklesSkin elasticityCellular longevity
Niveau d'évidence :Données humaines

Comments

Sign in to join the discussion

Avertissement : Ce stack est soumis par la communauté et est destiné à des fins de recherche uniquement. Peptide Contacts ne vérifie pas la sécurité ou l'efficacité des stacks soumis. Consultez toujours un professionnel qualifié de la santé avant d'utiliser tout protocole de péptides.